SIN-CHN SCIENTIFIC PRESS PTE.LTD.

Molecular & Cellular Biomechanics 2025, 22(4), 1496.
https://doi.org/10.62617/mcb1496

Article

Biomechanical and inflammatory pathways of IL-1β in ARDS: Insights from extensive burn injuries

Yiqi Yang, Guobao Huang*

Department of Burn and Plastic Surgery, Central Hospital Affiliated to Shandong First Medical University, Jinan 250013, China
*** Corresponding author:** Guobao Huang, 13370582872@126.com

CITATION

Yang Y, Huang G. Biomechanical and inflammatory pathways of IL-1β in ARDS: Insights from extensive burn injuries. Molecular & Cellular Biomechanics. 2025; 22(4): 1496. https://doi.org/10.62617/mcb1496

ARTICLE INFO

Received: 7 February 2025
Accepted: 21 February 2025
Available online: 10 March 2025

Abstract: Acute Respiratory Distress Syndrome (ARDS) is a severe complication often seen in patients with extensive burns, driven by systemic inflammation mediated by interleukin-1β (IL-1β). Understanding the biomechanical and inflammatory pathways, as well as long-term complications, is critical for improving therapeutic interventions. However, existing approaches often fail to comprehensively address the interplay between IL-1β and the systemic inflammatory response, particularly in the context of biomechanical stress on lung tissue, leading to limited efficacy in mitigating ARDS-related morbidity and mortality. Furthermore, these methods lack precise strategies to predict and monitor disease progression in burn patients, especially in terms of biomechanical alterations in pulmonary function. The proposed framework emphasizes ARDS as the focal point for addressing systemic inflammation in burn patients by targeting IL-1β-mediated inflammatory pathways (IL-1β-MIP) and their biomechanical consequences. The method integrates advanced biomarker analysis and molecular-level therapeutic interventions focusing on IL-1β inhibition to assess the impact of inflammation on lung compliance and tissue stiffness. The proposed approach utilizes a combination of precision medicine, including cytokine-modulating therapies, alongside early diagnostic tools such as IL-1β serum level monitoring. This framework aims to alleviate acute symptoms and mitigate the risk of long-term complications such as pulmonary fibrosis and immune dysregulation, which are often associated with altered tissue mechanics. The findings demonstrate that targeted IL-1β modulation significantly reduces ARDS severity, improving survival rates and reducing long-term complications. IL-1β-MIP highlights the potential of personalized anti-inflammatory therapies in transforming ARDS management in patients with extensive burns, providing a foundation for future clinical advancements that integrate biomechanical insights into therapeutic strategies.

Keywords: IL-1β; inflammation; biomechanics; pulmonary function; acute respiratory distress syndrome; clinical

1. Introduction

Often causing poor oxygenation and respiratory failure, acute respiratory distress syndrome is a serious illness defined by significant inflammation and lung damage [1]. In patients with extensive burn injuries, this is a common and maybe fatal side effect whereby the course of disease is much shaped by the systemic inflammatory response [2]. Driven mostly by pro-inflammatory cytokines including interleukin-1β (IL-1β), ARDS occurs in the framework of burn injuries resulting from both local pulmonary and systemic inflammatory processes [3]. Important coordinator of the inflammatory cascade, IL-1β affects several immunological and tissue responses affecting lung damage, capillary leakage, and respiratory failure [4].

ARDS in burn victims has a complicated etiology comprising a dysregulated inflammatory response starting in the skin following heat damage and spreading to several organs, including the lungs [5]. Although early healing depends on this systemic inflammatory response, too strong or protracted forms of it become maladaptive and aggravate lung damage and hinder recovery [6]. Especially IL-1β has been linked to ARD development by means of its effects on alveolar-capillary barrier breakdown, immune cell recruitment, and synthesis of other pro-inflammatory cytokines [7]. Although prior research have individually investigated the function of IL-1β in burn damage and lung inflammation, integrated methods aiming at the total inflammatory network are necessary to more effectively treat ARDS in burn patients [8]. According to recent epidemiological studies, the incidence of ARDS in burn patients is as high as 37%, with a mortality rate of 37.5% [9].

Many times, existing ARD-reducing medications are not very effective in addressing the fundamental causes of inflammation or forecasting disease development [9]. Many treatments center on non-specific anti-inflammatory drugs or general immunosuppression, which have little effect on burn patients where inflammation serves both defensively and destructively [10]. Better treatment effects might come from a more exact, focused strategy emphasizing on changing important cytokines such IL-1β [11]. Though the whole potential of these treatments is yet unclear, current developments in biomarker analysis and the creation of particular cytokine-targeting drugs provide fresh opportunities for treating ARDS [12].

The paper suggests a method to target inflammation in burn patients with ARDS through IL-1β mediation, with an emphasis on personalized therapy approaches [13]. Combining biomarketer-guided monitoring with cytokine-modulating treatments looks to lower inflammation, improve lung function, and lower the risk of long-term consequences like immunological dysfunction and pulmonary fibrosis [14]. This focused therapy offers a more customized and successful way to fight the systemic inflammation causing ARDS, therefore improving the prognosis of burn victims [15].

Motivation: The growing frequency of ARDS in burn patients emphasizes the need for tailored treatments to lower inflammation [16]. Emphasizing IL-1β-mediated pathways, our work intends to enhance therapy results and lessen long-term consequences, hence enhancing survival rates and quality of life for burn patients with ARD [17].

Problem statement: Current ARDS treatments for burn patients are insufficient to target the complicated, IL-1β-driven inflammatory pathways accelerating disease development. Current therapies are often non-specific and useless for long-term problems or prognosis [18]. Precision medicine combined with strategies aimed at IL-1β is desperately needed to enhance patient outcomes and lower morbidity and death linked with ARD.

Contribution of this paper:

- This paper elucidates IL-1β's critical role in triggering systemic inflammation and ARDS in burn patients, providing a detailed understanding of its contribution to disease progression and associated long-term complications.
- The paper proposes a novel ARDS management framework focusing on IL-1β modulation, combining advanced biomarker-based diagnostics and cytokine-

inhibiting therapies to enhance disease monitoring, mitigate acute inflammation, and reduce chronic pulmonary complications.

- By integrating personalized anti-inflammatory treatments and early detection tools, the paper demonstrates significant improvements in survival rates, reduced ARDS severity, and decreased long-term complications, setting the stage for advanced clinical interventions in burn patient care.

This paper is structured as follows: In section 2, the related work of ARDS is studied. In section 3, the proposed methodology of IL-1β-MIP is explained. In section 4, the efficiency of IL-1β-MIP is discussed and analyzed. Finally, in section 5, the paper concludes with future work.

2. Related work

Among the primary worldwide causes of mortality are both acute and chronic lung diseases, include Acute lung injury (ALI)/acute respiratory distress syndrome (ALI/ARDS). Effective treatments still appear unattainable even if understanding their complex nature has evolved. Emphasizing creative approaches like immunotherapy, antioxidant drugs, and molecular-targeted therapeutics for better outcomes, this collection discusses the roles of immune cells, biomarkers, inflammatory pathways, and therapeutic options.

2.1. Comprehensive Immunopathogenesis Analysis of ALI/ARDS

Emphasizing the roles of immune cells including dendritic cells (DCs), natural killer (NK) cells, phagocytes, and neutrophils this review highlights a comprehensive examination of the immunopathogenesis of ALI/ ARDS [19]. It underlines gut bacterial involvement, inflammatory pathways, and cytokine storms. The investigation aims to identify new pathways causing immune-mediated lung injury, therefore offering potential targets for innovative therapeutic techniques designed to improve treatment and prevention outcomes for ALI/ARD patients.

2.2. Integrated Pathophysiological and Molecular Mechanism-Based Therapeutics for ARDS

Emphasizing dysregulated inflammation, alveolar-capillary barrier failure, decreased alveolar fluid clearance, and oxidative stress [20], this method investigates the pathophysiology and molecular foundations of ARDS. Analyzing signaling pathways linked to these processes points to pharmacologic treatments, microRNA-based therapies, and mesenchymal stromal cell treatments among other therapeutic modalities. These treatments are investigated for their capacity to influence significant signal transduction pathways to reduce ARDS mortality and improve therapeutic results by addressing its complex pathophysiology.

2.3. HMGB1-TLR4 Pathway-Based Biomarker and Therapeutic Strategy for ARDS

It evaluates serum HMGB1 as a predictive biomarker for early ARDS diagnosis and mortality prediction in burn and smoke-inhalation injuries [21]. Lung activation under Toll-like receptor 4 (TLR4) was examined with HMGB1 levels. Investigated as

a targeted therapeutic approach was co-localizing HMGB1 and TLR4 and targeting systemic HMGB1 levels via mesenchymal stem cell (MSC) therapy. Blocking HMGB1 signals is proposed to lower ARD development and improve critical care scenario outcomes.

2.4. Antioxidant-Based Therapeutic Strategies for Acute and Chronic Lung Injuries

Emphasizing the functions of airway inflammation and oxidative stress [22], this paper investigates molecular and cellular mechanisms underlying acute and chronic lung damage. It looks at alternative innovative antioxidant-based drugs aimed to address lung pathology and challenges current therapies on symptom management. Aiming targeting oxidative damage and inflammation at the molecular level, these potential therapies seek to slow down disease development, improve healing, and prevent long-term injuries, therefore offering a promising approach for managing lung damage-associated morbidity and mortality.

2.5. Genomic and Pharmacological Targeting of Burn-Induced Lung Injury

Microarray data GSE7779 and GSE37069 revealed enhanced pathways and immune-related DEGs. Hub DEGs were validated by qPCR using clinical blood samples; the DGIdb database assisted in identifying potential drug candidates [23]. Pathology in a severe burn mouse model was used to examine these drugs for organ damage. ELISA-derived blood inflammatory indicators (IL-1β, IL-6, TNF-α, MCP-1) and NF-κB pathway activity were evaluated by Western blotting. Lung inflammatory-immune responses were elucidated by transcriptome sequencing, therefore confirming the therapeutic efficacy.

2.6. Immunotherapy Targets in ALI/ARDS

It focuses on immunotherapy of acute lung injury/ARDS by investigating the roles of many immune cells and cytokines involved in their pathogenesis [24]. Emphasizing their responsibilities to contribute to the inflammatory storm, the trademark of ALI/ARDS, it reveals the interaction between immune cells and cytokines. The study aims to identify new therapeutic targets and strategies using immune control to lower inflammation, therefore providing innovative routes for effective treatment of acute lung injury.

2.7. Comprehensive Analysis of Post-Burn Immunology and Inflammatory Mechanisms

Analyzing post-burn immunology, this narrative review emphasizes the prolonged and excessively powerful inflammatory response specific to burn injuries. It studies in local and systemic illness the roles of complement systems, acute phase proteins, pro- and anti-inflammatory mediators, lymphocyte activity changes, stress responses, and immune cell intrusion [25]. With an eye on furthering research and improving targeted therapeutic methods for burn-induced inflammation and associated

issues, the study notes knowledge gaps in understanding the basic mechanisms and their impact on clinical outcomes.

Stressing inflammation, oxidative stress, and immune cell dynamics, the studies suggest to immunological-mediated mechanisms causing lung damage. The creative solutions are stressing indicators such as HMGB1, immunotherapy, microRNA, antioxidant-based treatments, and post-burn immunological enhancement. These strategies aim to narrow therapeutic gaps, reduce mortality, and improve recovery in allied diseases including ALI/ARDS. The advantages and limitations of related work are listed in **Table 1**.

Table 1. Advantages and limitations of related work.

S. No	Methods	Advantages	Limitations
1	Comprehensive Immunopathogenesis Analysis of ALI/ARDS	● Highlights immune cell roles in pathogenesis. ● Identifies novel therapeutic targets.	● Limited by the complexity of immune interactions. ● May lack clinical validation.
2	Integrated Pathophysiological and Molecular Mechanism-Based Therapeutics for ARDS	● Targets key signaling pathways. ● Investigates multiple therapeutic modalities.	● Complex pathophysiology may complicate treatment development. ● Requires further clinical trials.
3	HMGB1-TLR4 Pathway-Based Biomarker and Therapeutic Strategy for ARDS	● Early diagnosis using HMGB1 as a biomarker. ● Potential targeted therapeutic approach with MSCs.	● Focuses only on HMGB1-TLR4 signaling. ● MSC therapy may have variable outcomes.
4	Antioxidant-Based Therapeutic Strategies for Acute and Chronic Lung Injuries	● Addresses oxidative stress and inflammation. ● Potential to improve healing and prevent long-term injury.	● Effectiveness of antioxidant drugs may vary. ● Long-term outcomes still unclear.
5	Genomic and Pharmacological Targeting of Burn-Induced Lung Injury	● Utilizes microarray data for biomarker identification. ● Involves pre-clinical validation in burn models.	● Limited to pre-clinical models, requiring clinical validation. ● High complexity in data analysis.
6	Immunotherapy Targets in ALI/ARDS	● Investigates immune modulation as a therapeutic approach. ● Identifies novel targets for reducing inflammation.	● Needs further clinical studies to confirm efficacy. ● Complex immune interactions complicate therapy development.
7	Comprehensive Analysis of Post-Burn Immunology and Inflammatory Mechanisms	● In-depth exploration of post-burn immune response. ● Identifies therapeutic gaps and future.	● Lacks detailed mechanistic understanding. ● Focuses more on theory than practical application.

3. Proposed method

It aims to look at the inflammatory pathways linked to the start of ARDS. Mediator between many pathways is interleukin-1 beta (IL-1β). More specifically, it stresses the sequence of events beginning with inflammation and working via endothelial damage and immune cell activation to lung injury, edema, and decreased gas exchange. From this follows the long-term consequences. Lung damage results from this chain of events.

3.1. Contribution 1: Targeting IL-1β-Mediated Inflammation in ARDS

ARDS in burn patients caused by interleukin-1β (IL-1β) is discussed in this current work. Moreover suggested as a therapeutic approach to reduce systemic inflammation are inflammatory pathways mediated by IL-1β-MIP. This study used

the enzyme-linked immunosorbent assay (ELISA) to detect IL-1β levels in serum. The kit was purchased from LiankeBio with batch number EK201BHS. The detection steps were strictly followed as per the kit instructions, with three replicates for each sample to ensure accuracy. Data analysis was conducted using SPSS 26.0 software, with *t*-tests and variance analysis applied, and a significance level of $p < 0.05$ was set. In clinical practice, patients are divided into low, medium, and high-risk groups based on their IL-1β levels upon admission. For high-risk patients, in addition to routine treatment, IL-1β inhibitors can be used early on, with an initial dose of 1.5 mg/kg, administered every week, for a treatment period of 6 weeks. At the same time, IL-1β levels are rechecked every 48 h during treatment, and the treatment plan is adjusted in a timely manner according to the trend of changes in IL-1β levels. In addition, regularly monitor lung function indicators such as lung compliance and oxygenation levels to comprehensively assess the treatment effect. Research shows that Anakinra has significant effects in controlling chronic inflammation and alleviating arthritis symptoms. It can effectively reduce acute phase reactions and improve joint function [25].

From severe burn injuries to ARDS, **Figure 1** shows the inflammatory cascade set off by IL-1β. It starts with damage of tissue producing DAMPs activating TLRs and NLRs and building the NLRP3 inflammasome. This generates IL-1β release that fuels a cytokine storm, endothelial dysfunction, and inflammatory cell invasion. Common of ARDS, these episodes finish in edema, alveolar injury, and poor gas exchange. The image emphasizes how burn injuries induce systematic inflammation, therefore connecting localized tissue damage to significant respiratory and systemic consequences like hypoxemia, sepsis, and organ malfunction.



Figure 1. IL-1β Cascade: The burn-to-ARDS pathway.

$$(l_p \to Bq''): \to Xaz[l - prw] + 4f[y - tw''] \quad (1)$$

The equation illustrates how $(l_p \to Bq'')$ interacts with systemic mediators of inflammation $Xaz[l - prw]$ and how these mediators impact downstream pathways $4f[y - tw'']$, worsening the severity of ARDS. Acute and long-term effects of ARDS in burn patients may be mitigated by focusing on IL-1β-driven systemic inflammation, as shown by this Equation (1).

$$(2st'' \to Ba): Ban[\forall - prt''] + Qab'' \quad (2)$$

Equation (2) explains how systemic inflammation $\forall - prt''$ is made worse by activating IL-1β, which in turn sets Qab'' off wide-ranging inflammatory cascades $(2st'' \to Ba)$ and increases pulmonary dysfunction Ban. In patients suffering from ARDS with severe burns, the equation lends credence to the framework's stated purpose of decreasing inflammation, enhancing lung function, and avoiding long-term consequences.

$$dq[lp - tv'']: \to Ba[frt''] + Pt[nv - dt''] \quad (3)$$

Equation (2) depicts the development of inflammation induced by IL-1β via $dq[lp - tv'']$ increased cytokine activity $Ba[frt'']$ and its effects on harm to tissues $Pt[nv - dt'']$ and pulmonary dysfunction. The precision medicine focus on inflammation reduction and better patient outcomes is further supported by the equation.

$$Fds[l - pat'']: \to Vq[k - 2st''] + 2xa'' \quad (4)$$

The feedback-driven systemic damage ($Fds[l - pat'']$) that is started by IL-1β, the responses to inflammation ($Vq[k - 2st'']$) that are propagated, and the exacerbation of tissue injury ($2xa''$) are all shown in Equation (4). The purpose of the equation is to highlight that the strategy aims to improve the treatment effectiveness in burn patients by minimizing acute inflammation and injury to tissues via accurate regulation of IL-1β.

Emphasizing the important role of IL-1β, **Figure 2** demonstrates how ARDS develops after significant burns. Starting with pulmonary and extrapulmonary insults, the process passes via epithelial and endothelial damage, therefore compromising the alveolar-capillary barrier. Activated by the NLRP3 inflammasome, IL-1β induces systemic inflammation, sets off cytokine cascades (TNF-α, IL-6, IL-8), and draws immune cells. These actions reduce surfactant production, produce lung edema, and poor gas exchange. Particularly crucial in long-term effects like immunological dysregulation and fibrosis are targeted IL-1β therapies. This paradigm connects burn injuries with ARDS prospective treatment strategies.



Figure 2. Burn-induced ARDS: Unraveling the IL-1β inflammatory network.

$$\propto_3 [K - pg]: \rightarrow Vq[\forall - 2pt''] + \forall pt'' \quad (5)$$

The IL-1β-driven pro-inflammatory signaling is amplified in the Equation (5) ($\propto_3 [K - pg]$), which in turn activates cytokines throughout the body $Vq[\forall - 2pt'']$ and keeps systemic inflammation going ($\forall pt''$). The framework's emphasis on reducing sudden symptoms and long-term problems in burn patients by breaking inflammatory cycles is further supported by the equation.

$$\forall_3 [L - pt]: Nj[\forall - prt''] + Aqw[p - 2pt''] \quad (6)$$

Through prolonged $Aqw[p-2pt'']$ inflammatory reactions $\forall_3[L-pt]$ and worsened pulmonary damage ($Nj[\forall-prt'']$), the systemic effects of IL-1β are shown in the Equation (6). The significance of precise therapy in reducing inflammation and avoiding acute and chronic consequences in burn patients is emphasized by the equation.

$$Sq[lo]:\rightarrow Ba[;[t]+Ga[wdf-ts'']] \tag{7}$$

The Equation (7) shows how localized IL-1β activity starts ($Sq[lo]$), culminates in systemic inflammatory signals ($Ba[;[t]$), and then causes damage specific to tissues ($Ga[wdf-ts'']$). The precision approach of the framework in minimizing inflammation generated by IL-1β and improving lung outcomes in people with burns is highlighted by the equation.

$$\partial_r t[ap-3sr'']:\rightarrow Ba[lp-rwt]-2ab'' \tag{8}$$

Equation (8) shows how IL-1β-driven inflammation pathways ($\partial_r t[ap-3sr'']$) affect systemic inflammatory responses ($Ba[lp-rwt]$) and how targeted therapies may reduce these responses ($2ab''$). To enhance clinical outcomes for patients with severe burns, the equation emphasizes the need to regulate systemic inflammation.

3.2. Contribution 2: Integration of Precision Medicine and Early Diagnostics

Tracking IL-1β blood level allows the framework to combine early diagnosis tools with cytokine-modulating drugs to improve disease prediction and monitoring. This makes tailored treatment possible as well as improved illness prediction.

Figure 3 graphs the IL-1β-mediated inflammatory pathways (IL-1β-MIP) linking early stimuli like as burns to the progression of ARDS. Starting with DAMPs releasing pattern recognition receptors and the NLRP3 inflammasome activating, the process generates IL-1β. The production of IL-1β results in the recruitment of immune cells, vascular damage and cytokine cascades which subsequently contributes to the systemic inflammatory response. Moreover, these processes lead to pulmonary vascular congestion, reduced gas exchange and alveolar destruction which leads to the development of ARDS. The framework indeed reinforces the assertion that IL-1β is key in relation to systemic inflammation and respiratory distress, it highlights the more persistent consequences such as fibrosis of the lungs and immune system imbalance.



Figure 3. IL-1β pathways: From inflammation to ARDS.

$$f_t[l - ptr'']: \rightarrow Qa[l - pw''] + 2bnt'' \tag{9}$$

Through $2bnt''$ increased production of cytokines ($f_t[l - ptr'']$) and subsequent reconstruction of tissues or damage (Qa), the Equation (9) depicts the evolution of IL-1β-induced activation ($[l - pw'']$). The equation backs up the framework's emphasis on targeted therapies to reduce inflammation and enhance burn patients' chances of full recovery.

$$\propto_g p[l - pw'']: \rightarrow 2xv'' + 3ept'' \tag{10}$$

Equation (10) shows how IL-1β signaling is amplified $\propto_g p$, which causes inflammatory responses $l - pw''$ to be enhanced $3ept''$ and pulmonary tissue damage

to be worsened. The equation highlights the goal of the framework, which is to use tailored medicines to reduce inflammation and safeguard lung function in individuals who have suffered severe burns.

$$\propto_m [lr' - tv]: \rightarrow Da[\forall - pwt''] + vb' + 3q \tag{11}$$

The proposed Equation (11) implies that the modulation of IL-1β ($\propto_m$) affects systemic inflammation responses ($lr^{'} - tv$), which in turn leads to pulmonary damage ($Da[\forall - pwt^{''}]$) and set off a complicated feedback loop ($vb^{'} + 3q$). Improving long-term patient outcomes after burn-induced acute respiratory distress syndrome (ARDS) is emphasized by the equation as being dependent on reducing the systemic effects of interleukin-1β.

$$r_g[l - pt]: \rightarrow QV - RV[L - PQ'']2qpt \tag{12}$$

The following Equation (12) depicts the systemic reaction $L - PQ^{''}$ and modification of pulmonary function $2qpt$ caused by IL-1β-driven inflammation: $r_g[l - pt]$ and the resulting worsening of injury: $QV - RV$. Burn patients with acute respiratory distress syndrome (ARDS) may rest certain that their strategy will help reduce inflammation, speed up the healing process in the lungs, and forestall any potential long-term consequences.

Beginning with an insult to the lung, be it from pulmonary or extra-pulmonary disorders, **Figure 4** explains the different phases of primary ARDS. The injury creates a breach in the alveolar-capillary barrier and increases the endothelial and epithelial permeability. This injury results in the collapse of alveoli. Damage to type II cells diminishes the synthesis of surfactant; this aggravates lung dysfunction as well. These processes cause atelectasis and lower lung capacities, therefore compromising lung compliance. Particularly in burn cases, this flowchart highlights the connected inflammatory pathways and cellular responses driving ARD development.



Figure 4. Pathophysiological pathways of lung injury in ARDS.

$$\partial\forall' - pt: \rightarrow \partial\forall[\propto +2q''] + 2av'' \quad (13)$$

Equation (13) depicts the process of IL-1β-driven inflammation activation $\partial\forall' - pt$ and modulation $\partial\forall[\propto +2q'']$, which in turn affects systemic cytokine responses $2av''$, which in turn causes more damage to the lungs. This strategy aims to alleviate burn patients' immediate complaints and long-term problems by reducing their IL-1β-mediated pathways, as shown in the equation.

$$V_f[l - prt]: \rightarrow Xq[2cs] - Sa[\partial t - pw''] \quad (14)$$

The evolution of inflammation generated by $V_f[l - prt]$, which intensifies cytokine signaling ($Xq[2cs]$), and reduces the repair of tissue mechanisms ($Sa[\partial t - pw'']$) are both shown by Equation (14). To decrease cytokine-induced harm and increase recovery from acute respiratory distress syndrome (ARDS) in burn patients, the equation highlights the approach's objective of targeting IL-1β pathways.

$$F_f[n - pa'']: \rightarrow Qw[m - nw''] + 4vaq'' \quad (15)$$

The beginning of inflammatory pathways $F_f[n - pa'']$ driven by IL-1β is shown by Equation (15), which shows increased release of cytokines $Qw[m - nw'']$ and consequent damage $4vaq''$ or malfunction of tissues. To alleviate both short-term inflammatory symptoms and long-term lung issues in burn patients, the suggested method aims to target IL-1β, as shown in the equation.

$$(lp[\forall - tw'']): = \rightarrow Vq[l - pt''] + Aqv'' \quad (16)$$

In this equation, $(lp[\forall - tw''])$ is the modification of IL-1β signaling pathways, which in turn cause $Vq[l - pt'']$ systemic inflammatory responses and Aqv'' worsened tissue damage or dysfunction. To alleviate both short-term symptoms and longer-term consequences linked to lung damage and inflammation, the equation emphasizes the method's goal of focusing on the analysis of IL-1β serum levels.

3.3. Contribution 3: Improved Long-Term Outcomes

It presents a workable strategy for better burn-related ARDS treatment. Analysis indicates that aiming targeting IL-1β might significantly reduce ARDS severity, raise survival rates, and minimize long-term effects like immunological dysregulation and lung fibrosis.

After defining the role of IL-1β in driving systemic inflammation, **Figure 5** takes on the question of whether ARDS and severe burns are related. The process begins with DAMP release and tissue damage due to burns, which further facilitates the activation of inflammasome, the synthesis of IL-1β, and its cascading effects on vascular leakiness and lung function. The use of cytokine targeting therapies such as precision medicine and biomarker monitoring; assist in ameliorating the severity of ARD in the IL-1β-MIP model. By reducing inflammation, improving pulmonary function, and avoiding sequelae like fibrosis, this approach indicates the potential of IL-1β-focused therapy to enhance survival and redefine ARDS treatment for burn patients.



Figure 5. Taming the fire: IL-1β's role in burn-induced ARDS.

$$C_f[l-pt'']:\rightarrow Ba[\cup -ptr''] + Qb[l-pt''] \tag{17}$$

Systemic inflammation $C_f[l-pt'']$ and the worsening of pulmonary damage ($Ba[\cup -ptr'']$) are represented by the equation, which is triggered by IL-1β-driven inflammatory pathways ($Qb[l-pt'']$). The method's objective of regulating IL-1β to lessen short-term and long-term consequences, enhance lung function, and speed up patient recovery is emphasized by Equation (17) for the analysis of pulmonary function.

$$(lpt''):\rightarrow Rq[l-pr''] + FDs[\delta v - 2pt''] \tag{18}$$

This Equation (18) implies that the IL-1β pathways are activated $FDs[\delta v - 2pt'']$, which in turn leads to stronger inflammatory reactions (lpt'')) and more tissue damage or dysfunction ($Rq[l-pr'']$). The equation emphasizes that the strategy aims to decrease acute inflammatory reactions and long-term consequences such as lung fibrosis by targeting IL-1β on the analysis of ARDS severity.

$$\partial_g[l-pw]'':\rightarrow Wq[m-nt''] + 3aq'' \tag{19}$$

The stimulation of inflammatory pathways mediated by IL-1β is shown in Equation (19), ($\partial_g[l-pw]''$), which induces an increased cytokine response $Wq[m-nt'']$ and worsens pulmonary damage ($3aq''$). To alleviate both short-term symptoms and long-term consequences linked to lung injury, the suggested approach

aims to target IL-1β, and the equation supports this objective for the analysis of survival rates.

$$\partial_b g[l - prt'']: \to Na[\times -pwr''] + 4w[l - pt''] \quad (20)$$

The stimulation of inflammation induced by IL-1β is shown by the equation ($\partial_b g\left[l - prt^{''}\right]$), which in turn exacerbates lung damage or dysfunction $4w\left[l - pt^{''}\right]$ and leads to higher cytokine production ($Na\left[\times -pwr^{''}\right]$). By reducing acute symptoms and preventing long-term pulmonary problems, Equation (20) highlights the method's objective of improving overall patient health by targeting IL-1β in the analysis of the Incidence of long-term complications.

The results of this analysis highlight the significance of interleukin-1 beta (IL-1β) in the onset of ARDS. This comes from burns. Lung damage may be caused by cytokine storms, inflammation, and endothelial dysfunction; this paper presents a thorough investigation of all these components. Targeting interleukin-1β in precision medicine can help to improve diagnosis, treatment, and long-term results, thereby reducing the severity of acute respiratory distress syndrome (ARDS) and avoiding consequences such lung fibrosis and immunological dysregulation.

4. Result and discussion

It analyzes the degree and course of ARDS in burn victims using many criteria. Pulmonary function, survival rates, the degree of ARDS, interleukin-1β (IL-1β) blood levels, and long-term consequences mostly take front stage. It demonstrates the need of inflammation and interleukin-1β (IL-1β) in creating tailored therapy plans.

Table 2. Simulation environment.

Metrics	Description
Gene Expression Profiles	Measurement of gene expression levels to identify differentially expressed genes (DEGs) associated with ALI/ARDS.
Functional Annotation (GO/KEGG)	Functional categorization and pathway analysis of DEGs to understand their biological roles in inflammation and immune response.
PPI Network	Construction of protein-protein interaction networks to identify key hub genes involved in immune and inflammatory pathways.
Immune Cell Infiltration	Assessment of immune cell types, especially M1 and M2 macrophages, within lung tissue during ALI/ARDS progression.
Macrophage Polarization	Evaluation of gene expression in M1 vs. M2 macrophages to assess macrophage polarization in ALI/ARDS.
ROC Analysis	Receiver operating characteristic analysis to evaluate the diagnostic potential of CD274 (PD-L1) in ARDS.
JAK-STAT3 Pathway Activation	Experimental analysis of JAK-STAT3 signaling pathway activation and its role in regulating CD274 (PD-L1) expression on M1 macrophages.
Proinflammatory Cytokine Production	Measurement of cytokine levels to understand the inflammatory response in M1 macrophages, especially after CD274 (PD-L1) knockdown.

Dataset Description: Emphasizing M1 macrophage polarization, this study identifies crucial genes connected to acute lung injury (ALI/acute respiratory distress syndrome). It underlines CD274 (PD-L1) as a potential biomarketer for ARDS diagnosis and a regulator of M1 macrophage polarization and proinflammatory

cytokine production by means of bioinformatics and experimental techniques [26]. The findings suggest new therapy goals for ALI/ARD management. **Table 2** describes the simulated environment and related analytical indicators in the study of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS).

4.1. Analysis of IL-1β serum levels

Measuring cytokine levels helps to evaluate burn patient inflammation under ARD by means of IL-1β serum level study. Strongly linked with severe systemic inflammation, higher IL-1β influences ARDS development (**Figure 6**). By means of regular monitoring these levels, one may estimate illness severity, which directs focused anti-inflammatory treatment. Given a high accuracy level of 97.14%, this study is rather important for customizing therapy and improving patient outcomes.



Figure 6. Analysis of IL-1β serum levels.

4.2. Analysis of pulmonary function

Burn patients with ARDS may test essential breathing parameters such as lung compliance and oxygenation by means of pulmonary function analysis. This analysis reveals the degree of lung damage and dysfunction caused by systematic inflammation. **Figure 7** shows With 93.81% accuracy, it guides doctors in determining the degree of respiratory compromise, so guiding appropriate treatments to maximize oxygen delivery, minimize lung damage, and so enhance general pulmonary functionality, so boosting patient recovery.



Figure 7. Analysis of pulmonary function.

4.3. Analysis of ARDS severity

For burn patients, ARD degree of lung damage is evaluated under clinical and radiological standards (**Figure 8**). This study aids in the classification of ARD into many phases, therefore directing the treatment decisions. With a somewhat low accuracy rate of 18.71%, however, it suggests that contemporary techniques for measuring ARD severity in burn patients may not completely represent the complexity of inflammation-driven lung damage. This implies the need of more accurately computed values.



Figure 8. Analysis of ARDS severity.

4.4. Analysis of survival rates

Studies of survival rate in burn patients with ARD look at how different treatment strategies affect patient outcomes. Raising survival rates depends much on early IL-1β management and respiratory assistance (**Figure 9**). This paper guide helps doctors to discover the best treatment choices and predict survival, thereby guiding therapy and prioritizing of patients at higher risk for death. With an accuracy percentage of 92.33%.



Figure 9. Analysis of survival rates.

4.5. Analysis of incidence of long-term complication

This paper rates in burn patients with ARD the frequency of long-term effects including immunological dysfunction and pulmonary fibrosis. Some of these problems

might be explained by increasing IL-1β levels and extended inflammation (**Figure 10**). The analysis, with a 95.65% accuracy level, points out people who could have chronic conditions, therefore advising preventive measures. Early identification of any long-term issues allows better post-discharge treatment, therefore enhancing the general quality of life for burn survivors.



Figure 10. Analysis of incidence of long-term complication.

The paper recommends monitoring burn patients with ARDS to see IL-1β blood levels and lung capacity changes. It examines how these policies, survival rates, and long-term effects may be tailored to each patient's specific needs, thereby generating better outcomes. This will help to explain more accurate assessments of ARDS degree of severity. The comparison between existing methods and proposed methods is shown in **Table 3**.

Table 3. Comparison of existing method and proposed method.

Aspects	Existing Method in Ratio	Proposed Method in Ratio	Key features
IL-1β Serum Levels	67.08%	97.14%	The proposed method provides a more accurate and reliable analysis of IL-1β serum levels, guiding targeted anti-inflammatory therapies and predicting ARDS progression.
Pulmonary Function	75.85%	93.81%	The proposed method offers higher accuracy in evaluating pulmonary function, enabling timely interventions to optimize oxygenation and lung recovery.
ARDS Severity	57.63%	18.71%	The existing method has higher accuracy, and the proposed method's low accuracy highlights the need for improved assessment tools for ARDS severity in burn patients.
Survival Rates	82.91%	92.33%	The proposed method shows an improved survival rate prediction, aiding in better treatment plans and patient management strategies.
Incidence of Long-term Complications	84.96%	95.65%	The proposed method provides better predictions of long-term complications, including pulmonary fibrosis and immune dysfunction, for improved post-care management.

IL-1β is a key mediator of immune responses and plays a critical role in both acute and chronic inflammatory reactions. Long-term suppression of IL-1β can alter the normal response patterns of the immune system, particularly in its ability to

respond to infections or other inflammatory stimuli. The immune system may experience a reduced ability to react to antigens, leading to a weakened defense against infections and an increased risk of infection. Moreover, prolonged IL-1β suppression may induce immune tolerance, weakening the immune system's response to specific pathogens or inflammatory signals. While this may alleviate excessive inflammation, it could also hinder the body's ability to effectively recognize and respond to new infections or lesions. Therefore, research assessing the long-term impact of IL-1β inhibitors on the immune system is crucial.

The efficacy analysis of IL-1β inhibition combined with conventional treatments in ARDS patients aims to evaluate whether there is a synergistic effect to improve patient outcomes. IL-1β plays a key role in the inflammatory response of ARDS, and inhibiting its action may help reduce lung inflammation and improve oxygenation. When IL-1β inhibition is used in conjunction with conventional treatments, such as mechanical ventilation or Extracorporeal Membrane Oxygenation (ECMO), it may further enhance the therapeutic effect by reducing immune and inflammatory responses triggered by these treatments. Combination therapy not only improves lung function and survival rates but may also reduce the occurrence of complications, thereby enhancing overall treatment outcomes. Clinical research and data analysis are conducted to explore the potential synergistic effects of IL-1β inhibition combined with conventional treatments, providing more effective strategies for the treatment of ARDS.

5. Conclusion

It shows especially in burn patients the crucial role interleukin-1β (IL-1β) plays in producing the systemic inflammation seen in acute respiratory distress syndrome (ARD). Main actor in the inflammatory processes leading to ARDS development and progression, IL-1β significantly influences patient outcomes. By focusing on IL-1β reduction, this approach offers a realistic way to reduce ARD severity, improve lung function, and lessen the likelihood of long-term effects such as immunological dysregulation and pulmonary fibrosis. Combining contemporary biomarketer analysis with precision medicine helps to show amazing accuracy in predicting disease development that instance, monitoring serum IL-1β levels and using cytokine-modulating medications. With the goal to guide tailored treatment regimens, it is vital to analyze IL-1β blood levels at 97.14% and pulmonary function at 93.81%. Early intervention and individualized treatment are needed, since the results suggest that targeted IL-1β control might be a good way to decrease ARD-related mortality and morbidity. More effective treatment strategies for burn patients may be achieved by addressing the intricate relationship between ARDS and systemic inflammation.

Future work

It should focus on enhancing diagnostic tools for more accurate assessment of ARD degree in burn patients given the poor accuracy 18.71% of current methods. Finding novel biomarkers and expanding the effect of IL-1β control in other inflammatory diseases would assist to better understand the full effects of systematic inflammation. Moreover crucial for verifying the proposed structure are clinical

investigations assessing the long-term success of IL-1β-targeted therapy in burn patients with ARD. Future studies should look at how combining IL-1β control with other immunotherapeutic modalities can have synergistic benefits to improve patient outcomes. Tracking how such therapies impact long-standing outcomes like lung fibrosis will need long-term follow-up analysis.

Author contributions: Conceptualization, GH and YY; methodology, YY; software, GH; validation, YY and GH; formal analysis, YY; investigation, YY; resources, GH; data curation, YY; writing—original draft preparation, YY; writing—review and editing, GH; visualization, YY; supervision, YY; project administration, GH; funding acquisition, YY. All authors have read and agreed to the published version of the manuscript.

Ethical approval: Not applicable.

Conflict of interest: The authors declare no conflict of interest.

References

1. McVey MJ, Steinberg BE, Goldenberg NM. Inflammasome activation in acute lung injury. American Journal of Physiology-Lung Cellular and Molecular Physiology. 2021; 320(2): L165–L178. doi: 10.1152/ajplung.00303.2020
2. Li N, Geng C, Hou S, et al. Damage-associated molecular patterns and their signaling pathways in primary blast lung injury: New research progress and future directions. International Journal of Molecular Sciences. 2020; 21(17): 6303. doi: 10.3390/ijms21176303
3. Niri P, Saha A, Polopalli S, et al. Role of biomarkers and molecular signaling pathways in acute lung injury. Fundamental & Clinical Pharmacology. 2024; 38(4): 640–657. doi: 10.1111/fcp.12987
4. Bossardi Ramos R, Adam AP. Molecular mechanisms of vascular damage during lung injury. In: Lung Inflammation in Health and Disease. Springer International Publishing; 2021. pp. 95–107.
5. Al-Benna S. Inflammatory and coagulative pathophysiology for the management of burn patients with COVID-19: Systematic review of the evidence. Annals of Burns and Fire Disasters. 2021; 34(1): 3–9.
6. Vaughn AE, Lehmann T, Sul C, et al. CNP-miR146a Decreases Inflammation in Murine Acute Infectious Lung Injury. Pharmaceutics. 2023; 15(9): 2210. doi: 10.3390/pharmaceutics15092210
7. Xu H, Sheng S, Luo W, et al. Acute respiratory distress syndrome heterogeneity and the septic ARDS subgroup. Frontiers in Immunology. 2023; 14. doi: 10.3389/fimmu.2023.1277161
8. Ziaka M, Exadaktylos A. Exploring the lung-gut direction of the gut-lung axis in patients with ARDS. Critical Care. 2024; 28(1): 179. doi: 10.1186/s13054-024-04966-4
9. An Y, Zhang H, Wang R, et al. Biomarkers, signaling pathways, and programmed cell death in acute lung injury and its treatment with Traditional Chinese Medicine: A narrative review. European Review for Medical & Pharmacological Sciences. 2023; 27(21).
10. Yin Y, Zeng Z, Wei S, et al. Using the sympathetic system, beta blockers and alpha-2 agonists, to address acute respiratory distress syndrome. International Immunopharmacology. 2024; 139: 112670. doi: 10.1016/j.intimp.2024.112670
11. Youssef NS, Elzaitony AS, Abdel Baky NA. Diacerein attenuate LPS-induced acute lung injury via inhibiting ER stress and apoptosis: Impact on the crosstalk between SphK1/S1P, TLR4/NFκB/STAT3, and NLRP3/IL-1β signaling pathways. Life Sciences. 2022; 308: 120915. doi: 10.1016/j.lfs.2022.120915
12. O'Donnell JS, Peyvandi F, Martin-Loeches I. Pulmonary immuno-thrombosis in COVID-19 ARDS pathogenesis. Intensive Care Medicine. 2021; 47(8): 899–902. doi: 10.1007/s00134-021-06419-w
13. Hu Q, Zhang S, Yang Y, et al. Extracellular vesicles in the pathogenesis and treatment of acute lung injury. Military Medical Research. 2022; 9(1). doi: 10.1186/s40779-022-00417-9
14. Guo X, Niu Z, Zhuang Y, et al. Bone marrow mesenchymal stromal cells attenuate smoke inhalation injury by regulating the M1/M2-Th17/Treg immune homeostasis axis. International Immunopharmacology. 2024; 141: 112986. doi: 10.1016/j.intimp.2024.112986

15. González-Rodríguez P, Herrero R, Sanchez G, Angel Lorente J. New insights in ARDS pathogenesis. Signa Vitae. 2022; 18(5).
16. Tan YY, Zhang DW, Yang C, et al. ASIC1a regulates airway epithelial cell pyroptosis in acute lung injury by NLRP3-Caspase1-GSDMD pathway. International Immunopharmacology. 2024; 143: 113623. doi: 10.1016/j.intimp.2024.113623
17. Lupu L, Palmer A, Huber-Lang M. Inflammation, thrombosis, and destruction: The three-headed cerberus of trauma- and SARS-CoV-2-induced ARDS. Frontiers in Immunology. 2020; 11. doi: 10.3389/fimmu.2020.584514
18. Zuo W, Tian F, Ke J, et al. Mechanisms and Research Progress of Traditional Chinese Medicine Regulating NF-κB in the Treatment of Acute Lung Injury/Acute Respiratory Distress Syndrome. Chinese Medicine and Natural Products. 2024; 04(03): e93–e105. doi: 10.1055/s-0044-1790228
19. Zheng J, Li Y, Kong X, Guo J. Exploring immune-related pathogenesis in lung injury: Providing new insights Into ALI/ARDS. Biomedicine & Pharmacotherapy. 2024; 175: 116773. doi: 10.1016/j.biopha.2024.116773
20. Huang Q, Le Y, Li S, Bian Y. Signaling pathways and potential therapeutic targets in acute respiratory distress syndrome (ARDS). Respiratory Research. 2024; 25(1): 30. doi: 10.1186/s12931-024-02678-5
21. Young MD, Cancio TS, Thorpe CR, et al. Circulatory HMGB1 is an early predictive and prognostic biomarker of ARDS and mortality in a swine model of polytrauma. Frontiers in Immunology. 2023; 14. doi: 10.3389/fimmu.2023.1227751
22. Xiang Y, Pan B han, Zhang J, et al. Suppression of overactivated immunity in the early stage is the key to improve the prognosis in severe burns. Frontiers in Immunology. 2024; 15. doi: 10.3389/fimmu.2024.1455899
23. Bezerra FS, Lanzetti M, Nesi RT, et al. Oxidative Stress and Inflammation in Acute and Chronic Lung Injuries. Antioxidants. 2023; 12(3): 548. doi: 10.3390/antiox12030548
24. Zhu W, Zhang Y, Wang Y. Immunotherapy strategies and prospects for acute lung injury: Focus on immune cells and cytokines. Frontiers in Pharmacology. 2022; 13. doi: 10.3389/fphar.2022.1103309
25. Korkmaz HI, Flokstra G, Waasdorp M, et al. The Complexity of the Post-Burn Immune Response: An Overview of the Associated Local and Systemic Complications. Cells. 2023; 12(3): 345. doi: 10.3390/cells12030345
26. Available online: https://datasetsearch.research.google.com/search?src=0&query=Inflammatory%20Pathways%20of%20IL-1%CE%B2%20in%20ARDS&docid=L2cvMTF5OThwdzlxNg%3D%3D (accessed on 3 December 2024).